Combined chemotherapy and 125I-particle implantation for treatment of children with head and neck soft tissue sarcomas improve the short-term efficacy: Beijing Children's Hospital experience over 2 years

被引：0

作者：

Duan, Chao ^{[1
,2
,3
]}

Zheng, Lei ^{[4
]}

Jin, Mei ^{[1
,2
,3
]}

Zhang, Dawei ^{[1
,2
,3
]}

Zhao, Wen ^{[1
,2
,3
]}

Wang, Xisi ^{[1
,2
,3
]}

Zhao, Qian ^{[1
,2
,3
]}

Li, Xingjun ^{[1
,2
,3
]}

Zhang, Jianguo ^{[4
]}

Ma, Xiaoli ^{[1
,2
,3
]}

Zheng, Huyong ^{[1
,2
,3
]}

机构：

[1] Capital Med Univ, Beijing Childrens Hosp, Beijing Key Lab Pediat Hematol Oncol, 56 Nanlishi Rd, Beijing, Peoples R China

[2] Capital Med Univ, Beijing Childrens Hosp, Natl Key Discipline Pediat, Minist Educ, 56 Nanlishi Rd, Beijing, Peoples R China

[3] Capital Med Univ, Beijing Childrens Hosp, Hematol Oncol Ctr, 56 Nanlishi Rd, Beijing, Peoples R China

[4] Peking Univ, Dept Oral & Maxillofacial Surg, Sch & Hosp Stomatol, Beijing 100871, Peoples R China

来源：

INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE | 2016年 / 9卷 / 06期

关键词：

I-125 seed implantation; head and neck sarcomas; children; chemotherapy; PARAMENINGEAL RHABDOMYOSARCOMA; INTERNATIONAL SOCIETY; PEDIATRIC ONCOLOGY;

D O I：

暂无

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Objective: To evaluate the efficacy of chemotherapy combined with I-125 seed implantation in treating pediatric head and neck soft tissue sarcomas. Methods: The clinical characteristics, overall survival rate, local control rate and event free survival rate of patients treated with chemotherapy and 125I seed implantation were studied retrospectively. Results: There were 12 males and 2 female patients. Age at diagnosis ranged between 1.0-10.7 years, and the median age is 4.9 years. Only 3 of the patients had localized disease, the other 11 patients had metastatic disease. The follow up time ranged from 8 to 30.5 months, median follow up time was 12.3 months. The overall response rate (complete response, very good patial response and partial response; CR, VGPR and PR) for all 14 patients was 85%, including 6/14 patients with CR, 1/14 patient with VGPR, 5/14 patients with PR. 2/14 patients had progressive disease. The overall local control rate was 85%, with a median LC time 18.9 months (95% CI: 16.4 to 21.3 month). The overall survival rate in this group of patients was 100%. The overall survival time was 8 to 30.5 months. The event free survival rate was 85%, with a median EFS time 18.9 months (95% CI: 16.4 to 21.3 months). Hematological toxicity was the most common side effects of chemotherapy. 7 of 14 patients suffered from grade 1 or 2 skin reaction after seed implantation. Conclusions: Chemotherapy combined with I-125 seed implantation is a feasible treatment for children with head and neck sarcomas, with high local control rates and event free survival.

引用

页码：11901 / 11906

页数：6